跳至主要内容
临床试验/NCT03943420
NCT03943420Unknown不适用

One Research on Application of Key Technologies About Improving Cognitive Impairment Caused by Hypertension With the Therapy of Early Intervention With Qianyang Yuyin Granules

Jiangsu Famous Medical Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2018年12月28日最近更新:
适应症

试验速览

阶段
不适用
入组人数
144
试验地点
1
主要终点
Changes of brain image

研究概览

简要总结

Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive impairment caused by hypertension.

详细描述

Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive impairment caused by hypertension.

The investigators designed a multi-center randomized controlled clinical trial to study the security and effectiveness of this therapy.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
55 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 55 to 75 years old, male or female;
  • Having a history of hypertension for more than 2 years but can maintain SBP ≤ 140 mmHg and BDP ≤ 90 mmHg with medication;
  • 21 ≤ MMSE < 26, or 14 ≤ MoCA < 26, CDR < 0.
  • Bseides, the chief complaint must happen after having hypertension;
  • Meet TCM Syndrome Differentiation Standard:according to the Guidelines for the Clinical Research of Chinese Medicine New Drugs ( published by China Medical Science Press ) :Overabundant liver-fire type:dizziness and headache, both face and eyes are red, dry mouth and bitter taste in mouth, red tongue with yellowish coating, wire and frequent pulse. Yin deficiency and yang hyperactivity type: dizziness and headache, Tinnitus and forgetfulness, sphoria with feverish sensation in chest & palms & soles, palpitation and insomnia, red tongue & thin white or less coating, wiry weak and numbered pulse;
  • CTMRI hint: leukoaraiosis and no sign of Cerebral infarction;
  • Patients or the guardian hold the right opinions over the research and are willing to obey researcher's orders;
  • Having a certain degree of education (being able to read simple newspapers in the past);
  • Patients agree to sign informed consent。

排除标准

  • Secondary hypertension;
  • Taking certain kinds of antihypertensive drugs which may damage brain cognitive function;
  • Diagnosed as depression or other mental disorders according to DSM-IV;
  • Diagnosed as vascular dementia according to diagnostic criteria, CDR ≥ 0.5; alzheimer disease or dementia caused by some other reasons (including mixed dementia according to diagnostic criteria for VCI); cognitive impairment due to head injury。
  • Suffering from certain kinds of diseases which may interfere the assessment of cognitive function, including those who are diagnosed as alcoholics and drugs or psychotropic medicine abusers during the last 5 years according to DSM-IV;
  • Accompanied with severe neurological function disorder;
  • Asthma, chronic severe primary cardiovascular disease, liver lesion, hematological lesions, lung diseases, diabetes or other severe diseases may influence the patients' survival such as cancer or AIDS;
  • Other: Such as poor compliance, or can not attend the follow-up visit in time for some reasons;
  • Taking the same kind of medicine during the last 30 days which may influence the trial;
  • Is participating in another clinical study;
  • Not up to TCM Syndrome Differentiation Standard。

结局指标

主要结局

Changes of brain image

时间窗: 24 weeks

Measure and record the volume changes of diseased alba, the micro-structure changes of alba fasciculus by MRI to see if the therapy effect or not.

Measure and assess the changes of VaDAS-cog ( Vascular Dementia Assessment Scale cognitive subscale ) among time points

时间窗: 12 weeks, 24 weeks, 48 weeks

Measure and record with VaDAS-cog

次要结局

  • Metabonomics(24 weeks)
  • Measure and assess the changes of MMSE ( Mini-mental State Examination ) among time points(12 weeks, 24 weeks, 48 weeks)
  • Measure and assess the changes of CDR ( Clinical Dementia Rating ) among time points(12 weeks, 24 weeks, 48 weeks)
  • Measure and assess the changes of ADL ( Activity of Daily Living ) among time points(12 weeks, 24 weeks, 48 weeks)
  • Incidence rate of outcome event(24 weeks)
  • Therapeutic effect(24 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验